Kalbe Farma Launches Serplulimab to Revolutionize Cancer Treatment in Indonesia – Expert Insights

Liputan6.com, Jakarta – PT Kalbe Farma Tbk (Kalbe) launched the drug Serplulimab through its subsidiaries, PT Kalbe Genexine Biologics (KGbio) and PT Global Onkolab Farma (GOF). This step was taken to expand health access for cancer fighters and increase innovation in the development of cancer immunotherapy in Indonesia.

The Chairman of the Indonesian Association of Internal Medicine Hematology Oncology Medical Doctors (PERHOMPEDIN), Dr. Dr. Tubagus Djumhana Atmakusuma SpPD KHOM, explained that cancer is the biggest health problem and occupies the second position as the highest cause of death after cardiovascular disease. According to GLOBOCAN data in 2022, every year there will be around 408 thousand new cases of cancer with a mortality rate of 243 thousand.

Tubagus also stated that lung cancer is the third most common type of cancer, and more than 50 percent of patients diagnosed with lung cancer have a death rate within one year after being diagnosed and their life expectancy is only 17.8 percent.

“Therefore, management of lung cancer cases requires a comprehensive approach,” he said at the Serplulimab launch event on Saturday, March 9 2024. The launch is the result of collaboration with Shanghai Henlius Biotech Inc. This was done after Kalbe obtained a distribution permit from the Republic of Indonesia Food and Drug Monitoring Agency (BPOM RI) in December 2023.

On the same occasion, Consultant Hematology Oncology Doctor at Cipto Mangunkusumo Hospital (RSCM), Dr Dr Andhika Rachman SpPD-KHOM, added that lung cancer is often diagnosed in hospitals at an advanced stage when treatment options are limited.

2024-03-11 00:32:27
#Lung #Cancer #Immunotherapy #Drug #Serplulimab #Launched #Indonesia